Compare TWST & CERT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TWST | CERT |
|---|---|---|
| Founded | 2013 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Retail: Computer Software & Peripheral Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.5B |
| IPO Year | 2018 | 2020 |
| Metric | TWST | CERT |
|---|---|---|
| Price | $40.36 | $9.18 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 10 |
| Target Price | ★ $44.67 | $12.78 |
| AVG Volume (30 Days) | 1.2M | ★ 2.3M |
| Earning Date | 02-02-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.07 |
| Revenue | $376,572,000.00 | ★ $415,551,000.00 |
| Revenue This Year | $15.19 | $10.80 |
| Revenue Next Year | $15.10 | $6.47 |
| P/E Ratio | ★ N/A | $138.82 |
| Revenue Growth | ★ 20.32 | 11.47 |
| 52 Week Low | $23.30 | $8.03 |
| 52 Week High | $55.33 | $15.69 |
| Indicator | TWST | CERT |
|---|---|---|
| Relative Strength Index (RSI) | 71.61 | 49.37 |
| Support Level | $34.55 | $9.10 |
| Resistance Level | $37.73 | $9.87 |
| Average True Range (ATR) | 1.79 | 0.28 |
| MACD | 0.59 | 0.07 |
| Stochastic Oscillator | 93.96 | 42.39 |
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well-plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies and powers cost-effective, rapid high-throughput synthesis, enabling researchers to realize opportunities ahead rapidly. Geographically, it derives a majority of its revenue from the United States.
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval and increase patient access to medicines. The company has its business presence in the Americas which is also it key revenue generating market, EMEA and Asia Pacific region.